<DOC>
	<DOCNO>NCT02525432</DOCNO>
	<brief_summary>The purpose study determine effect intravenous infusion autologous bone marrow mononuclear cell ( BMMNC ) brain structure neurocognitive/functional outcome severe traumatic brain ( TBI ) injury adult . The primary objective determine intravenous infusion autologous BMMNC severe TBI result structural preservation global gray matter ( GM ) volume white matter ( WM ) volume integrity ; well select region interest corpus callosum . THe secondary objective determine autologous BMMNC infusion improve functional neurocognitive deficit adult TBI ; reduce neuroinflammatory response TBI ; evaluate spleen size splenic blood flow time use ultrasound corresponding change inflammatory cytokine ; infusion relate toxicity long-term follow-up safety evaluation .</brief_summary>
	<brief_title>Autologous Stem Cell Study Adult TBI ( Phase 2b )</brief_title>
	<detailed_description>Traumatic brain injury associate 33 % trauma related death . There effective therapy treat secondary brain injury post-injury response CNS apoptosis neuroinflammation . Pre-clinical Phase I clinical progenitor cell therapy show promise TBI/stroke via ( 1 ) promotion CNS structural preservation , ( 2 ) reduce neuroinflammatory response injury . This randomized , blind , Bayesian CRM dose-escalation placebo-controlled study design treat severe , acute TBI adult patient IV infusion autologous bone marrow mononuclear cell . 55 adult TBI patient randomize receive single IV infusion BMMNs ( 6 x 10^6 9 x 10^6 ) placebo . Study subject consecutive admission adult severe TBI meeting inclusion/exclusion criterion . Adults , age 18-55 year , hospitalize Memorial Hermann Hospital ( Houston , Texas ) severe TBI ( GCS 3-8 ) screen eligibility . Informed consent , bone marrow/sham harvest , stem cell/placebo infusion must take place within 48 hour initial injury . Following consent baseline procedure , subject randomize 3:2 ratio ( use permute block stratify GCS 3-4 5-8 ) autologous BMMNC infusion ( n=33 ) placebo ( n = 22 ) , respectively . Administration begin low dose ( i.e . 6 x 10^6 cells/kg body weight ) dose give cohort 3 subject treat BMMNC ( note : cohort size refers subject treat autologous BMMNC ) . After cohort 3 subject treat autologous BMMNC infusion ( accumulated average every 5.5 adult randomize ) , dosage next cohort 3 autologous BMMNC-treated subject determine CRM base finding subject previously treat prior probability likelihood toxicity assign investigator start study . At dos , algorithm design avoid administer dos p ( toxicity ) exceed 0.15 . Subjects monitor closely infusion relate toxicity complication first 14 day post-infusion also receive usual standard care traumatic brain injury . Safety outcome assessment perform 1 6 month post-injury study visit .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>1 . Adults 18 55 year age day injury , 2 . Nonpenetrating closed head trauma . 3 . Glasgow Coma Score ( GCS ) 3 8 , ( best unmedicated postresuscitation score screening ) . 4 . Ability obtain legally authorize representative consent participation complete BMMNC/Sham harvest cell/placebo infusion within 48 hour initial injury . 5 . Ability speak English Spanish . 1 . Known history : 1. previous brain injury , 2. intellectual deficiency psychiatric condition likely invalidate ability assess postinjury change cognition behavior , 3. neurologic impairment and/or deficit , 4. seizure disorder require anticonvulsant therapy , 5. recently treat significant infection , 6. renal disease/altered renal function ( postresuscitation serum creatinine &gt; 1.5 mg/dL ) , 7. chronic hepatic disease alter liver function ( postresuscitation SGPT &gt; 150 U/L , and/or T. Bilirubin &gt; 1.3 mg/dL ) , 8. cancer , 9 . Chemical ETOH dependency , 10. immunosuppression ( admission WBC &lt; 3X103 ) , 11 . HIV positive status ; 2 . Obliteration perimesencephalic cistern initial head CT/MRI suggest prolonged hypoxic ischemic insult ; 3 . Initial hospital ICP &gt; 40 mm Hg ; 4 . Hemodynamic instability time consent define SBP &lt; 90mmHg , ongoing fluid resuscitation and/or requirement inotropic support maintain MAP normal age include CPP base inotropic support ; 5 . Uncorrectable coagulopathy time screening ; 6 . Unstable pelvic fracture require operative fixation ; 7 . Pulmonary contusion define chest xray nonanatomic opacification and/or PaO2 : FiO2 ratio &lt; 250 associate mechanism injury ; 8 . Greater AAST Grade III solid hollow visceral injury abdomen and/or pelvis diagnose CT imaging ; 9 . Spinal cord injury diagnose CT MR image clinical finding ; 10 . Persistent hypoxia define SaO2 &lt; 94 % &gt; 30 minute occur time hospital admission time consent ; 11 . Positive pregnancy test ; 12 . Concurrent participation interventional drug/device research study ; 13 . Unwillingness return followup visit ; 14 . Contraindications MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mesenchymal Stromal Cells , Multipotent</keyword>
	<keyword>Multipotent Mesenchymal Stromal Cells</keyword>
	<keyword>Stem Cells , Mesenchymal</keyword>
</DOC>